Conclusions This pilot study suggests VG added to HFOV would attenuate fluctuation of SpO₂ and pCO₂, which leads to prevent hypoxia and hypocapnia, possibly resulting in preferable neonatal prognosis.

PO-0735 NASAL HFOV WITH BINASAL PRONGS IS EFFECTIVE AND FEASIBLE IN ELBW NEWBORNS

S Aktas, S Unal, E Ergenekon, C Turkyilmaz, I Hirfanoglu, Y Atalay. *Division of Newborn Medicine, Gazi University, Ankara, Turkey*

10.1136/archdischild-2014-307384.1375

Introduction Noninvasive ventilation with nasal CPAP (n-CPAP), or nasalintermittant positive pressure ventilation (n-IPPV) is becoming standard of care in preterm. Limited experience has been reported with nasal high frequency oscillatory ventilation (n-HFOV). We present 2 newborns treated by n-HFOV applied with binasal prongs (Ram cannula Neotech) and Draeger Babylog 8000+ ventilator.

Cases 1. A 900 gr. 28 weeks gestation infant was intubated, given surfactant and ventilated by volume guarantee pressure-support ventilation for RDS. On 2nd day HFOV was started due to worsening respiratory status. On 11th day patient was extubated to n-HFOV and continued for 4 days followed by n-IPPV/n-CPAP.

2. A 830 gr. 28 weeks gestation infant was resuscitated in the delivery room. RDS and pulmonary interstitial emphysema was detected on radiography and surfactant was given. At 12 h pneumothorax occurred necessitating thoracic tube insertion and HFOV. Conventional ventilation was tried several times without success. HFOV continued for 46 days then baby was extubated to n-HFOV. Patient required reintubation after 4 days due to sepsis.

Abstract PO-0735 Table 1 Respiratory support and blood gas data of 2 patients are presented.

	Case 1			Case 2		
	HFO	nHFO 4 h	nHFO 24 h	HFO	nHFO 4 h	nHFO 24 h
PH	7.27	7.31	7.25	7.32	7.24	7.26
PCO ₂	53	47.5	45.7	30.8	35.5	36.6
PO ₂	63.5	61.7	100	58.8	67	59.1
FiO ₂	27	50	30	30	30	30
Amplitude	70	100	100	85	85	85
MAP	10	13	13	10	10	10

Conclusion n-HFOV with binasal prongs could be an alternative for preterms after prolonged HFOV.

PO-0736 PRELIMINARY EXPERIENCE WITH THE USE OF NEURALLY ADJUSTED VENTILATORY ASSIST IN THE NEONATE

F García-Muñoz Rodrigo, SM Rivero Rodriguez, A Florido Rodríguez, FG Martín Cruz, GM Galán Henríquez, R Díaz Pulido. *Neonatology, Complejo Hospitalario Universitario Insular-Materno Infantil de Canarias, Las Palmas de Gran Canaria, Spain*

10.1136/archdischild-2014-307384.1376

Background and aims Invasive and non-invasive ventilation of the neonate may be associated with local and systemic complications due to mechanical trauma to lung tissues and their

inflammatory response. A key objective of mechanical ventilation is to reduce its duration and side effects. Neurally Adjusted Ventilatory Assist (NAVA), a method that uses the electrical activity of the diaphragm (EAdi) as a signal to trigger the mechanical ventilatory breaths, may improve synchronisation between patient and ventilator and optimise the gas volume delivered to the lungs, according to the patient needs, eventually reducing volume- and biotrauma. We aimed to test the effectiveness of NAVA in the neonate.

Methods We present three preterm babies with severe respiratory distress syndrome that failed several attempts of weaning and extubation, and two full-term new-borns with amniotic fluid aspiration that could be successfully managed after changing from conventional ventilation to NAVA.

Results Our most frequent observations were a reduction in the Peak Inspiratory Pressure and in the need of FiO₂, after changing from S-IMV, A/C or Pressure Regulated Volume Control to NAVA. We also observed a reduction in respiratory rate and an increase in the patients' comfort. After extubation, during NIV-NAVA, the patients remained stable and comfortable, even with the presence of air-leaks up to 90%. No patient required reintubation.

Conclusions NAVA is effective in weaning and extubation of neonates and seems to provide more comfort to the patients. Further studies are needed to assess whether short-term benefits are reflected in better outcomes in the long run.

PO-0737 PROPHYLACTIC SURFACTANT IN THE VERY PRETERM INFANT: CLINICAL PRACTICE SUPPORTS ADHERENCE TO EUROPEAN GUIDELINES ON RDS

¹A Abrantes, ²AM Graca, ¹J Coelho, ¹R Carreira, ²M Abrantes, ²C Moniz. ¹Department of Pediatrics, Lisbon Academic Medical Center, Lisboa, Portugal; ²NICU – Department of Pediatrics, Lisbon Academic Medical Center, Lisboa, Portugal

10.1136/archdischild-2014-307384.1377

Background and aims Surfactant replacement therapy is key in the management of neonatal respiratory distress syndrome (RDS). Despite guideline updates on prophylactic surfactant (PS) use are increasingly more restrictive, outcomes remain improving. We aim to study clinical implementation of the 2010 update on management of RDS in very preterm infants in a tertiary NICU.

Methods Retrospective analysis of very preterm infants admitted to our NICU between 2010–2012. European 2010 RDS guidelines were progressively implemented during this period. We were able to compare patient characteristics and clinical outcomes of three groups: A) Fulfilled 2010 guidelines for PS; B) Did not fulfil 2010 guidelines and B1) Were given or B2) Were not given PS.

Results 277 preterms were admitted and divided into 3 groups: A) 75 fulfilled 2010 PS criteria; B1) 84 had PS despite absent criteria; B2) 118 did not have PS. Subgroup B1 had lower GA (29.1/30.3, p < 0.001) and lower BW than subgroup B2 (1175/1297 g, p < 0.01), but no significant differences were found in Apgar scores, CRIB or SNAPPE2. Subgroup B1 had higher rates of invasive ventilation than subgroup B2 (48/29%, p < 0.01), but lower need of rescue surfactant (11/31%, p < 0.002). No significant differences in mortality, chronic lung disease, length of stay or intraventricular haemorrhage were found.

Conclusions All the preterms who fulfilled 2010 criteria were given PS. Considering infants not fulfilling the 2010 criteria, outcomes were not different between those who got PS and